The leading market experts have placed a mean price target of $107.50 on IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $0.51 a share for the upcoming quarter and $2.36 for the current fiscal.
The technical analysis of IDEXX Laboratories, Inc. plainly substantiates that the 50-day moving average of IDEXX Laboratories, Inc. is $96.56, and stock is trading $14.11 points away or +14.61% from its 50-day moving average of $96.56. Further it is trading $26.59 or +31.63% away its 200-day moving average of $84.08. IDEXX Laboratories, Inc. (NASDAQ:IDXX) 52-week high is $111.37 and the 52-week low is $63.48.
This explains if the stock moves $-0.70, it will post a 52-week high. In event of +74.34% decline, a 52-week low will be hit.
Taking the valuation aspect to emphasize the valuation of IDEXX Laboratories, Inc., shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, IDEXX Laboratories, Inc. (NASDAQ:IDXX) ratio came in at 50.17.
The stock last ended the trading session at $110.67 and registered a market cap of $9.91B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. IDEXX Laboratories, Inc. (NASDAQ:IDXX) PEG ratio is at 3.49.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...